2.2 Lung-Protective Mechanical Ventilation

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

2.2 Lung-Protective Mechanical Ventilation

Key Takeaways Explain This Topic AI

The ARMA trial established that low-tidal-volume ventilation targeted strictly to 6 mL/kg of predicted body weight (PBW) reduces hospital mortality from 39.8% to 31.0% compared to conventional 12 mL/kg PBW ventilation.

Tidal volume must always be calculated using predicted body weight based on biological sex and height, never actual body weight, to prevent severe volutrauma to the restricted 'baby lung'.

End-inspiratory plateau pressure (Pplat) reflects static alveolar distension and must be maintained <= 30 cmH2O; if Pplat exceeds 30 cmH2O, tidal volume should be titrated down in 1 mL/kg decrements to as low as 4 mL/kg PBW.

Driving pressure (Delta P = Pplat - PEEP = Vt / Crs) directly reflects cyclical parenchymal strain; maintaining Delta P < 14-15 cmH2O is the physiological variable most strongly correlated with ARDS survival.

Permissive hypercapnia is well tolerated to an arterial pH of 7.20-7.25, but is strictly contraindicated in acute intracranial hypertension, severe right ventricular failure / acute cor pulmonale, and life-threatening hemodynamic instability.

Last updated: October 2026

Mechanisms of Ventilator-Induced Lung Injury (VILI)

Mechanical ventilation in ARDS is a double-edged sword: while indispensable for maintaining life-sustaining gas exchange, the physical forces generated by positive-pressure ventilation can directly initiate, amplify, and perpetuate parenchymal destruction—a phenomenon termed Ventilator-Induced Lung Injury (VILI) . The four classical mechanical mechanisms of VILI comprise:

Volutrauma : Overdistension of aerated alveoli at end-inspiration. Regional overdistension fractures the epithelial and endothelial architecture, ruptures intercellular junctions, and creates gross alveolar-capillary barrier disruption.

Barotrauma : High transpulmonary pressure ( P tp = P alv − P pl P_{\text{tp}} = P_{\text{alv}} - P_{\text{pl}} P tp ​ = P alv ​ − P pl ​ ) resulting in macroscopic alveolar rupture and air leak into extra-alveolar tissue planes, manifesting as pneumothorax, pneumomediastinum, and subcutaneous emphysema.

Atelectrauma : High shear stress generated by the repetitive cyclic collapse and reopening of unstable, surfactant-deficient alveolar units during each respiratory cycle at low end-expiratory pressures.

Biotrauma : Mechanical deformation activates stretch-activated ion channels and intracellular kinase cascades (including NF- κ \kappa κ B), triggering massive local production and systemic translocation of pro-inflammatory cytokines (IL-6, IL-8, TNF- α \alpha α ). Biotrauma links local pulmonary mechanical trauma to distant end-organ apoptosis, precipitating multisystem organ failure.

The "Baby Lung" Concept

In 1986, Gattinoni and colleagues demonstrated with quantitative CT that ARDS lungs are not stiff and uniformly diseased throughout. Instead, dependent lung regions are collapsed, fluid-filled, and consolidated, while non-dependent regions remain normally aerated. The functional, aerated fraction of lung tissue—the "baby lung" —has the anatomical volume and compliance of a healthy 5-to-6-year-old child (often only 200 to 400 mL of functional aerated parenchyma). Delivering a conventional tidal volume ( 10 – 12 mL/kg 10\text{--}12\text{ mL/kg} 10 – 12 mL/kg ) into this restricted baby lung causes catastrophic regional hyperinflation, cyclic overstretch, and accelerated mortality.

The ARDSNet ARMA Protocol: Low Tidal Volume Strategy

The pivotal ARDSNet ARMA trial (NEJM 2000) evaluated 861 patients randomized to either a traditional ventilation strategy ( 12 mL/kg 12\text{ mL/kg} 12 mL/kg PBW, aiming for plateau pressure ≤ 50 cmH 2 O \le 50\text{ cmH}_2\text{O} ≤ 50 cmH 2 ​ O ) or a lung-protective ventilation strategy ( 6 mL/kg 6\text{ mL/kg} 6 mL/kg PBW, aiming for plateau pressure ≤ 30 cmH 2 O \le 30\text{ cmH}_2\text{O} ≤ 30 cmH 2 ​ O ). The low-tidal-volume arm demonstrated an absolute 8.8% mortality reduction (31.0% vs. 39.8%, p = 0.007 p = 0.007 p = 0.007 ) and significantly more ventilator-free days (12 vs. 10 days, p = 0.007 p = 0.007 p = 0.007 ).

Predicted Body Weight (PBW) Calculation

Alveolar dimensions and total lung volume correlate with adult standing height and biological sex, determined by thoracic skeletal geometry. Adipose tissue does not increase alveolar capacity. Ventilating an obese patient based on actual body weight results in lethal volutrauma.

Male PBW (kg) = 50 + 0.91 × ( Height in cm − 152.4 ) = 50 + 2.3 × ( Height in inches − 60 ) \text{Male PBW (kg)} = 50 + 0.91 \times (\text{Height in cm} - 152.4) = 50 + 2.3 \times (\text{Height in inches} - 60) Male PBW (kg) = 50 + 0.91 × ( Height in cm − 152.4 ) = 50 + 2.3 × ( Height in inches − 60 ) Female PBW (kg) = 45.5 + 0.91 × ( Height in cm − 152.4 ) = 45.5 + 2.3 × ( Height in inches − 60 ) \text{Female PBW (kg)} = 45.5 + 0.91 \times (\text{Height in cm} - 152.4) = 45.5 + 2.3 \times (\text{Height in inches} - 60) Female PBW (kg) = 45.5 + 0.91 × ( Height in cm − 152.4 ) = 45.5 + 2.3 × ( Height in inches − 60 )

Height (ft / in) Height (cm) Male PBW (kg) Male Target V T V_T V T ​ ( 6 mL/kg 6\text{ mL/kg} 6 mL/kg ) Female PBW (kg) Female Target V T V_T V T ​ ( 6 mL/kg 6\text{ mL/kg} 6 mL/kg )

• 5'0" (60 in) 152.4 cm 50.0 kg 300 mL 45.5 kg 273 mL
• 5'3" (63 in) 160.0 cm 56.9 kg 341 mL 52.4 kg 314 mL
• 5'6" (66 in) 167.6 cm 63.8 kg 383 mL 59.3 kg 356 mL
• 5'9" (69 in) 175.3 cm 70.7 kg 424 mL 66.2 kg 397 mL
• 6'0" (72 in) 182.9 cm 77.6 kg 466 mL 73.1 kg 439 mL
• 6'3" (75 in) 190.5 cm 84.5 kg 507 mL 80.0 kg 480 mL
• Stepwise Implementation and Titration Rules

Calculate PBW and set initial tidal volume to 8 mL/kg 8\text{ mL/kg} 8 mL/kg PBW in Volume Assist-Control mode.

Titrate V T V_T V T ​ down by 1 mL/kg 1\text{ mL/kg} 1 mL/kg PBW every 1 to 2 hours until the target of 6 mL/kg 6\text{ mL/kg} 6 mL/kg PBW is reached.

Measure plateau pressure ( P plat P_{\text{plat}} P plat ​ ) using an end-inspiratory pause of 0.5 to 1.0 second during passive ventilation.

If P plat > 30 cmH 2 O P_{\text{plat}} > 30\text{ cmH}_2\text{O} P plat ​ > 30 cmH 2 ​ O , titrate V T V_T V T ​ downward in 1 mL/kg 1\text{ mL/kg} 1 mL/kg PBW decrements to 5 mL/kg 5\text{ mL/kg} 5 mL/kg and, if necessary, to 4 mL/kg 4\text{ mL/kg} 4 mL/kg PBW.

If P plat < 25 cmH 2 O P_{\text{plat}} < 25\text{ cmH}_2\text{O} P plat ​ < 25 cmH 2 ​ O and V T < 6 mL/kg V_T < 6\text{ mL/kg} V T ​ < 6 mL/kg PBW, V T V_T V T ​ may cautiously be increased by 1 mL/kg 1\text{ mL/kg} 1 mL/kg PBW until P plat > 25 cmH 2 O P_{\text{plat}} > 25\text{ cmH}_2\text{O} P plat ​ > 25 cmH 2 ​ O or V T = 6 mL/kg V_T = 6\text{ mL/kg} V T ​ = 6 mL/kg .

• Plateau Pressure and Driving Pressure
• Plateau Pressure ( P plat P_{\text{plat}} P plat ​ )

Peak inspiratory pressure ( P peak P_{\text{peak}} P peak ​ ) measured by the ventilator reflects the total pressure required to overcome both airway resistance and respiratory system elastance ( P peak = P resistive + P elastic P_{\text{peak}} = P_{\text{resistive}} + P_{\text{elastic}} P peak ​ = P resistive ​ + P elastic ​ ). In contrast, performing an end-inspiratory pause stops gas flow ( F = 0 F = 0 F = 0 ). When flow ceases, resistive pressure drops to zero, and the observed pressure equilibrates throughout the tracheobronchial tree to equal plateau pressure ( P plat P_{\text{plat}} P plat ​ ) . Plateau pressure represents the true peak static distending pressure experienced by the alveoli:

P plat = V T C rs + PEEP P_{\text{plat}} = \frac{V_T}{C_{\text{rs}}} + \text{PEEP} P plat ​ = C rs ​ V T ​ ​ + PEEP

The ARMA trial established a strict safety ceiling of P plat ≤ 30 cmH 2 O P_{\text{plat}} \le 30\text{ cmH}_2\text{O} P plat ​ ≤ 30 cmH 2 ​ O . Above 30 cmH 2 O 30\text{ cmH}_2\text{O} 30 cmH 2 ​ O , alveolar overdistension and barotrauma accelerate sharply.

Driving Pressure ( Δ P \Delta P Δ P )

In a landmark individual patient-data meta-analysis of 3,562 ARDS patients across 9 randomized trials, Amato and colleagues (NEJM 2015) identified that driving pressure ( Δ P \Delta P Δ P ) was the single mechanical variable most strongly correlated with survival:

Δ P = P plat − PEEP = V T C rs \Delta P = P_{\text{plat}} - \text{PEEP} = \frac{V_T}{C_{\text{rs}}} Δ P = P plat ​ − PEEP = C rs ​ V T ​ ​

Driving pressure normalizes tidal volume to the patient's individual respiratory system compliance ( C rs C_{\text{rs}} C rs ​ ), directly indexing the cyclic strain delivered to the aerated "baby lung":

An increase in driving pressure > 14 – 15 cmH 2 O > 14\text{--}15\text{ cmH}_2\text{O} > 14 – 15 cmH 2 ​ O is independently associated with an exponential rise in in-hospital mortality.

Isolated changes in PEEP or tidal volume only improve survival if they successfully reduce Δ P \Delta P Δ P .

Clinical PEEP Titration via Δ P \Delta P Δ P : When PEEP is increased by 2 cmH 2 O 2\text{ cmH}_2\text{O} 2 cmH 2 ​ O , if P plat P_{\text{plat}} P plat ​ rises by less than 2 cmH 2 O 2\text{ cmH}_2\text{O} 2 cmH 2 ​ O (or remains unchanged), driving pressure drops, indicating successful alveolar recruitment (improved compliance). Conversely, if P plat P_{\text{plat}} P plat ​ rises by more than the PEEP increment, Δ P \Delta P Δ P increases, signaling that the added PEEP is causing dangerous alveolar overdistension without recruitment.

Tip

Target a driving pressure Δ P < 14 cmH 2 O \Delta P < 14\text{ cmH}_2\text{O} Δ P < 14 cmH 2 ​ O . When confronting high plateau pressures or hypoxemia, driving pressure provides an immediate bedside indicator of whether ventilator adjustments are recruiting lung units or producing overdistension.

PEEP Titration and Clinical Trial Evidence

Positive end-expiratory pressure prevents end-expiratory alveolar collapse, increases functional residual capacity (FRC), decreases intrapulmonary shunt, and reduces cyclic atelectrauma. However, excessive PEEP causes alveolar overdistension, increases physiological dead space, compresses pulmonary capillaries, and compromises right ventricular cardiac output.

Higher vs. Lower PEEP: The Major Trials

Three major randomized trials evaluated higher vs. lower PEEP strategies combined with 6 mL/kg 6\text{ mL/kg} 6 mL/kg PBW ventilation:

ALVEOLI (ARDSNet, NEJM 2004) : Compared the lower-PEEP and higher-PEEP/FiO2 tables in 549 unselected ARDS patients (mean PEEP on days 1 to 4: 8.3 8.3 8.3 vs. 13.2 cmH 2 O 13.2\text{ cmH}_2\text{O} 13.2 cmH 2 ​ O ). Found no significant difference in hospital mortality (24.9% with lower PEEP vs. 27.5% with higher PEEP).

LOVS (Canadian Critical Care Trials Group, JAMA 2008) : Compared lower PEEP with high PEEP targeting P plat ≤ 40 cmH 2 O P_{\text{plat}} \le 40\text{ cmH}_2\text{O} P plat ​ ≤ 40 cmH 2 ​ O . Found no significant difference in hospital mortality (36.4% with the open-lung strategy vs. 40.4% with control).

EXPRESS (French ARDS Study Group, JAMA 2008) : Compared minimal distension (PEEP 5 – 9 cmH 2 O 5\text{--}9\text{ cmH}_2\text{O} 5 – 9 cmH 2 ​ O ) vs. maximal recruitment (PEEP titrated to maintain P plat P_{\text{plat}} P plat ​ at 28 – 30 cmH 2 O 28\text{--}30\text{ cmH}_2\text{O} 28 – 30 cmH 2 ​ O ). Found no significant difference in 28-day mortality (31.2% with minimal distension vs. 27.8% with increased recruitment).

The Briel Meta-Analysis (JAMA 2010)

An individual patient data meta-analysis by Briel and colleagues pooled 2,299 patients from these three trials. While higher PEEP showed no benefit across the unselected population, there was a treatment-by-subgroup interaction based on oxygenation severity :

Moderate to Severe ARDS ( PaO 2 / FiO 2 ≤ 200 mmHg \text{PaO}_2/\text{FiO}_2 \le 200\text{ mmHg} PaO 2 ​ / FiO 2 ​ ≤ 200 mmHg ) : Higher PEEP produced a statistically significant reduction in hospital mortality (adjusted relative risk 0.90, 95% CI 0.81-1.00, p = 0.049 p = 0.049 p = 0.049 ).

Mild ARDS ( PaO 2 / FiO 2 > 200 mmHg \text{PaO}_2/\text{FiO}_2 > 200\text{ mmHg} PaO 2 ​ / FiO 2 ​ > 200 mmHg ) : Higher PEEP conferred no survival benefit and showed a nonsignificant trend toward harm (relative risk 1.37, 95% CI 0.98-1.92, p = 0.07 p = 0.07 p = 0.07 ), plausibly from overdistension and hemodynamic compromise.

• ARDSNet Lower PEEP / Higher FiO 2 \text{FiO}_2 FiO 2 ​
• FiO 2 \text{FiO}_2 FiO 2 ​ 0.30 0.40 0.40 0.50 0.50 0.60 0.70 0.70 0.70 0.80 0.90 0.90 0.90 1.00
• PEEP \text{PEEP} PEEP 5 5 8 8 10 10 10 12 14 14 14 16 18 18-24

• ARDSNet Higher PEEP / Lower FiO 2 \text{FiO}_2 FiO 2 ​
• FiO 2 \text{FiO}_2 FiO 2 ​ 0.30 0.30 0.30 0.30 0.30 0.40 0.40 0.50 0.50 0.50-0.80 0.80 0.90 1.00 1.00
• PEEP \text{PEEP} PEEP 5 8 10 12 14 14 16 16 18 20 22 22 22 24
• The ART Trial (Cavalcanti et al., JAMA 2017)

The Brazilian ART trial randomized 1,010 patients with moderate-to-severe ARDS to receive either lung recruitment maneuvers with incremental PEEP titration targeting best compliance or standard ARDSNet low PEEP. The recruitment maneuver protocol utilized stair-step PEEP inflations up to 45 cmH 2 O 45\text{ cmH}_2\text{O} 45 cmH 2 ​ O and plateau pressures up to 60 cmH 2 O 60\text{ cmH}_2\text{O} 60 cmH 2 ​ O .

The recruitment maneuver group had a statistically significant increase in 28-day mortality (55.3% vs. 49.3%, hazard ratio 1.20, 95% CI 1.01-1.42, p = 0.041 p = 0.041 p = 0.041 ), higher 6-month mortality (65.3% vs. 59.9%), more barotrauma (5.6% vs. 1.6%), more pneumothorax requiring drainage (3.2% vs. 1.2%), and more hemodynamic compromise. The 2024 ATS guideline makes a strong recommendation against prolonged high-pressure recruitment maneuvers, and the 2026 Surviving Sepsis Campaign recommends against an incremental PEEP titration strategy in sepsis-associated moderate-to-severe ARDS.

Permissive Hypercapnia & Clinical Contraindications

Permissive hypercapnia is the intentional acceptance of respiratory acidosis resulting from low-tidal-volume ventilation, prioritizing alveolar protection over normal acid-base values.

Clinical Management Targets

Accept an arterial pH ≥ 7.20 – 7.25 \text{pH} \ge 7.20\text{--}7.25 pH ≥ 7.20 – 7.25 , allowing PaCO 2 \text{PaCO}_2 PaCO 2 ​ to rise up to 60 – 80 mmHg 60\text{--}80\text{ mmHg} 60 – 80 mmHg .

Set the respiratory rate up to 35 breaths/min to assist with CO 2 \text{CO}_2 CO 2 ​ clearance, but evaluate for intrinsic PEEP (auto-PEEP) via an end-expiratory pause to prevent air-trapping.

Minimize instrumental dead space: substitute heat and moisture exchangers (HMEs) with heated water-bath humidifiers, and remove unnecessary flexible catheter extensions.

Routine continuous sodium bicarbonate infusions to correct permissive hypercapnia do not improve clinical outcomes; bicarbonate infusion generates dissolved CO 2 \text{CO}_2 CO 2 ​ , which rapidly diffuses across cell membranes and paradoxically worsens intracellular acidosis.

Absolute & Relative Contraindications to Permissive Hypercapnia

Permissive hypercapnia is strictly contraindicated or must be heavily restricted in the following scenarios:

Severe Intracranial Hypertension / Acute Brain Injury : Hypercapnia triggers cerebral arteriolar vasodilation, dramatically increasing cerebral blood volume and provoking lethal spikes in intracranial pressure (ICP).

Severe Right Ventricular Failure / Acute Cor Pulmonale : Hypercapnic acidosis stimulates potent pulmonary arterial vasoconstriction, acutely elevating pulmonary vascular resistance (PVR). In patients with right ventricular dysfunction, this induces acute RV decompensation, septal flattening, and cardiogenic shock.

Severe Metabolic Acidosis : When underlying lactic acidosis or renal failure already reduces pH < 7.15 < 7.15 < 7.15 , superimposed respiratory acidosis precipitates profound systemic hypotension, refractory catecholamine unresponsiveness, and malignant ventricular arrhythmias.